Abstract 5113
Background
BioRAIDs is a supervised longitudinal collection of tumor and blood together with clinical outcome data in 419 primary cervical cancer patients from 7 European countries (NCT02428842).
Methods
Molecular analysis [Next Generation Sequencing (NGS) at SeqOmics (Hungary) & Reverse Phase Protein array (RPPA) at Institut Curie] was performed on quality-controlled primary tumor samples in 295 patients (70%) who subsequently had received primary radio chemotherapy (RCT). Integrative bioinformatics analyses were performed to identify pathway activations suggesting the need for additional/different therapies.
Results
NGS demonstrated driver Tyrosine Kinase Receptor/ PI3 kinase (TKR/PI3K) pathway mutations in 27%; TKR/PI3K + epigenetic pathway alterations (MLL2, MLL3) in 32 % and epigenetic alterations alone in 13% of patients. At a median follow up of 19 months [2-38], tumors for which no mutations in relevant genes from the TKR/PI3K pathways nor alterations in genes involved in epigenetic signaling appeared to be associated with a significantly better prognostic profile: HR = 2.4 [95% CI: 1.1 – 5.2]. RPPA analysis was carried out separating patients in 3 subgroups according to signaling pathway activation [EMT (epithelial mesenchymal transition), DNA damage and MAPK/PI3K], none of which was associated with bad prognosis.
Conclusions
The high frequency of epigenetic alterations with or without TKR/PI3K pathway mutations, suggests that epigenetically acting drugs (VorinostatR) may be relevant for patients whose tumors have genetic mutations of significance in epigenetically acting enzymes. Relevance of copy number alterations and of other frequently mutated genes (CSMD3, SYNE1), needs to be integrated and cross validated in a larger complementary dataset.
Clinical trial identification
NCT02428842.
Legal entity responsible for the study
Institut Curie.
Funding
This project has received founding from the European Union’s Seventh Program for research, technological development and demonstration under grant agreement No 304810.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
846 - Genomic characteristics of standardized uptake value of 18F-fluorodeoxy-glucose positron emission tomography in breast cancer
Presenter: Seon-Kyu Kim
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1297 - Characterization of PD-L1, CD8, CD3, CD68 and PanCK in Tumor Microenvironment of Gl Tract Tumors with respect to Patients’ Mismatch Repair Status and Anti-PD-1 Treatment Outcome using 5Plex IHC and Whole Slide Image Analysis
Presenter: Wenjun Zhang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1771 - Exhaustion of Platelet Kinetics and its Implication in Post-resection HCC Recurrence
Presenter: Bibek Aryal
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1953 - Progastrin, a new blood biomarker for the diagnostic and therapeutic monitoring, in gastro-intestinal cancers: A BIG-RENAPE project.
Presenter: Benoit You
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2104 - A new biomarker of breast cancer stage and patient response to neoadjuvant chemotherapy: HLA-DR expression in cytotoxic and regulatory T cells
Presenter: Diana Saraiva
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2830 - LungBEAM: A prospective multicenter trial to monitor EGFR mutations using BEAMing technology in Stage IV NSCLC patients
Presenter: Pilar Garrido Lopez
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
Slides
3262 - Immune checkpoints and liver resection after neoadjuvant chemotherapy including bevacizumab in patients with colorectal liver metastases
Presenter: Stefan Stremitzer
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4511 - Gene expression (GE)-based biomarkers associated with nivolumab response in a real-life cohort of patients with metastatic non-small cell lung cancer (mNSCLC)
Presenter: Nina Radosevic-Robin
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4670 - Association of microRNA-21 (miR-21) with efficacy of cetuximab (cet) and bevacizumab (bev) in patients with metastatic colorectal cancer (mCRC) within the FIRE-3 study (AIO KRK-0306)
Presenter: Lisa Miller-Phillips
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3518 - Molecular heterogeneity assessment by NGS in non-small cell lung cancer (NSCLC) harboring EGFR mutations: results of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France study.
Presenter: Hélène Blons
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract